ropinirole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2402 91374-21-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ropinirol
  • requip
  • ropinirole
  • ropinirole hydrochloride
  • ropinirole HCl
Ropinirole is a non-ergoline dopamine agonist. The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is thought to be related to its ability to stimulate dopamine D2 receptors within the caudate-putamen in the brain.
  • Molecular weight: 260.38
  • Formula: C16H24N2O
  • CLOGP: 2.80
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -2.87
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 133 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.32 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 55 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.60 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.970 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.222 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 19.907 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 4.853 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 81.740 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 81.360 % Moderate 0.78
herg hERG pIC50 4.953 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 2.455 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 16.866 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 74.030 % Moderate 0.78
kinase-safety-class ACVR2A,ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 36
kinase-selectivity-class AXL,CAMK2D,CDK4,EIF2AK3,GRK2,MAP2K6,MAPK7,PDK4,SIK2,STK33,TEK,TTK 12
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.133 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 69.663 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 80.440 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.310 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 84.030 % Moderate 0.78
rh-clint Rat hepatocyte intrinsic clearance 146.218 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.120 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 79.060 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 866.962 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2019 PMDA Hisamitsu Pharmaceutical Co., Inc.
Sept. 19, 1997 FDA GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 338.43 13.95 184 28303 36350 90563610
On and off phenomenon 307.92 13.95 84 28403 2459 90597501
Compulsive shopping 200.98 13.95 47 28440 722 90599238
Hallucination 192.14 13.95 162 28325 65797 90534163
Hallucination, visual 161.88 13.95 97 28390 22995 90576965
Dopamine dysregulation syndrome 157.29 13.95 30 28457 156 90599804
Restless legs syndrome 153.92 13.95 93 28394 22377 90577583
Full blood count abnormal 130.06 13.95 101 28386 36496 90563464
Fall 128.51 13.95 387 28100 481423 90118537
Tremor 124.88 13.95 194 28293 152979 90446981
Stoma site discharge 122.85 13.95 39 28448 1950 90598010
Freezing phenomenon 118.02 13.95 37 28450 1775 90598185
Impulse-control disorder 107.63 13.95 30 28457 952 90599008
Stoma site erythema 91.02 13.95 29 28458 1467 90598493
Hyperglycaemia 90.23 13.95 95 28392 50875 90549085
Bradykinesia 88.31 13.95 43 28444 6745 90593215
Gait disturbance 87.75 13.95 228 28259 260268 90339692
Hyperkinesia 83.93 13.95 29 28458 1890 90598070
Gambling 78.78 13.95 18 28469 248 90599712
Systemic lupus erythematosus 77.24 13.95 11 28476 361885 90238075
Glossodynia 75.61 13.95 7 28480 321772 90278188
Contraindicated product administered 75.12 13.95 7 28480 320132 90279828
Infusion related reaction 69.96 13.95 22 28465 416758 90183202
Parkinsonism hyperpyrexia syndrome 69.66 13.95 16 28471 226 90599734
Product dose omission issue 66.30 13.95 222 28265 291465 90308495
Treatment failure 63.09 13.95 10 28477 303918 90296042
Gambling disorder 62.92 13.95 21 28466 1231 90598729
Hepatic enzyme increased 62.42 13.95 18 28469 360718 90239242
Joint swelling 59.42 13.95 43 28444 503257 90096703
Muscle rigidity 58.60 13.95 43 28444 14266 90585694
Gastrooesophageal reflux disease 58.44 13.95 148 28339 166189 90433771
Delusion 57.61 13.95 42 28445 13798 90586162
Asthma 56.52 13.95 186 28301 241974 90357986
Feeling abnormal 54.84 13.95 145 28342 167090 90432870
Jealous delusion 50.80 13.95 10 28477 63 90599897
Exposure during pregnancy 49.12 13.95 8 28479 238402 90361558
Balance disorder 46.94 13.95 98 28389 96982 90502978
Parkinsonian gait 46.68 13.95 14 28473 578 90599382
Lower respiratory tract infection 44.29 13.95 12 28475 250647 90349313
Muscle injury 43.82 13.95 3 28484 176651 90423309
Withdrawal syndrome 43.49 13.95 44 28443 22480 90577480
Stomatitis 43.46 13.95 16 28471 274682 90325278
Wound 42.58 13.95 21 28466 302959 90297001
Arthropathy 42.27 13.95 32 28455 366210 90233750
Impaired healing 41.77 13.95 11 28476 234188 90365772
Stoma site pain 41.75 13.95 16 28471 1401 90598559
Acute psychosis 41.55 13.95 20 28467 3058 90596902
Posture abnormal 40.84 13.95 19 28468 2692 90597268
Illusion 39.87 13.95 15 28472 1249 90598711
Abnormal dreams 39.83 13.95 31 28456 11226 90588734
Irritable bowel syndrome 38.44 13.95 9 28478 207439 90392521
Dystonia 38.36 13.95 36 28451 16783 90583177
Drug intolerance 38.08 13.95 51 28436 447540 90152420
Hypersexuality 37.53 13.95 12 28475 614 90599346
Multiple sclerosis relapse 36.77 13.95 62 28425 52243 90547717
Behaviour disorder 36.50 13.95 21 28466 4614 90595346
Ill-defined disorder 36.35 13.95 7 28480 184884 90415076
Drug withdrawal syndrome 36.33 13.95 45 28442 28678 90571282
Stoma site reaction 35.94 13.95 10 28477 315 90599645
Depression 34.61 13.95 186 28301 300415 90299545
Insomnia 34.19 13.95 200 28287 333274 90266686
Alopecia 34.02 13.95 65 28422 495006 90104954
Binge eating 33.83 13.95 11 28476 594 90599366
Tension 32.56 13.95 18 28469 3664 90596296
Urinary tract infection 31.78 13.95 184 28303 305448 90294512
Discomfort 31.60 13.95 24 28463 274311 90325649
Psychotic symptom 31.49 13.95 15 28472 2241 90597719
Blood cholesterol increased 31.43 13.95 13 28474 207999 90391961
Polyp 31.37 13.95 23 28464 7621 90592339
Muscle spasms 31.15 13.95 159 28328 251724 90348236
Somnolence 30.93 13.95 139 28348 208945 90391015
Memory impairment 30.60 13.95 133 28354 197111 90402849
Rapid eye movement sleep behaviour disorder 29.90 13.95 9 28478 376 90599584
Oromandibular dystonia 29.85 13.95 10 28477 593 90599367
Multiple sclerosis 29.56 13.95 40 28447 27800 90572160
Pyrexia 29.20 13.95 108 28379 660377 89939583
Catecholamines urine increased 28.93 13.95 5 28482 13 90599947
Off label use 27.76 13.95 218 28269 1102034 89497926
Limbic encephalitis 27.75 13.95 8 28479 287 90599673
Death 27.61 13.95 241 28246 456310 90143650
Mental impairment 27.52 13.95 30 28457 16690 90583270
Rheumatoid arthritis 26.32 13.95 46 28441 362568 90237392
Parkinsonism 26.29 13.95 27 28460 14038 90585922
Anxiety 26.26 13.95 177 28310 309595 90290365
Blister 26.08 13.95 25 28462 254973 90344987
Therapy interrupted 25.88 13.95 52 28435 50056 90549904
Bursitis 25.84 13.95 5 28482 131649 90468311
Injury 25.78 13.95 15 28472 197334 90402626
Impulsive behaviour 25.68 13.95 12 28475 1718 90598242
Stoma site infection 25.54 13.95 10 28477 928 90599032
Pleurothotonus 25.35 13.95 11 28476 1324 90598636
Dizziness 24.53 13.95 288 28199 588996 90010964
Stereotypy 24.32 13.95 8 28479 448 90599512
Tardive dyskinesia 24.17 13.95 23 28464 10907 90589053
Device issue 23.45 13.95 37 28450 29500 90570460
Wound infection 23.23 13.95 3 28484 106399 90493561
Nasal congestion 23.06 13.95 68 28419 83346 90516614
Therapeutic response unexpected 22.57 13.95 31 28456 21849 90578111
Abdominal discomfort 22.44 13.95 76 28411 477252 90122708
Febrile neutropenia 22.19 13.95 11 28476 158338 90441622
Stoma site irritation 22.10 13.95 7 28480 347 90599613
Gastrointestinal disorder 22.06 13.95 29 28458 256658 90343302
Eczema eyelids 22.03 13.95 7 28480 351 90599609
Speech disorder 22 13.95 46 28441 45539 90554421
Haemorrhoids 21.97 13.95 34 28453 26668 90573292
Extra dose administered 21.73 13.95 20 28467 9098 90590862
Fibroma 21.72 13.95 9 28478 967 90598993
Inflammation 21.37 13.95 15 28472 178577 90421383
Reduced facial expression 21.26 13.95 12 28475 2541 90597419
Completed suicide 21.12 13.95 96 28391 144962 90454998
Irritability 20.85 13.95 39 28448 35623 90564337
Therapeutic product effect variable 20.77 13.95 10 28477 1529 90598431
Occipital neuralgia 20.75 13.95 8 28479 712 90599248
Psoriatic arthropathy 20.45 13.95 25 28462 228310 90371650
Serotonin syndrome 20.39 13.95 40 28447 37847 90562113
Chronic obstructive pulmonary disease 20.23 13.95 60 28427 73769 90526191
Major depression 20.10 13.95 20 28467 10015 90589945
General physical health deterioration 19.96 13.95 52 28435 355063 90244897
Spinal operation 19.83 13.95 20 28467 10176 90589784
Dropped head syndrome 19.75 13.95 6 28481 259 90599701
Pre-existing condition improved 19.72 13.95 19 28468 9150 90590810
Weight decreased 19.65 13.95 194 28293 379716 90220244
Akinesia 19.63 13.95 10 28477 1726 90598234
Device occlusion 19.52 13.95 19 28468 9263 90590697
Liver disorder 19.27 13.95 7 28480 121262 90478698
Resting tremor 19.17 13.95 8 28479 875 90599085
Surgery 19.04 13.95 43 28444 44844 90555116
Secondary hypertension 18.95 13.95 6 28481 297 90599663
Abnormal behaviour 18.88 13.95 29 28458 22599 90577361
Hypertension 18.79 13.95 77 28410 457455 90142505
Stoma site extravasation 18.74 13.95 6 28481 308 90599652
Sudden onset of sleep 18.66 13.95 7 28480 578 90599382
Therapeutic response shortened 18.64 13.95 29 28458 22850 90577110
Movement disorder 18.57 13.95 33 28454 28986 90570974
Back pain 18.41 13.95 166 28321 317009 90282951
Periodic limb movement disorder 18.38 13.95 7 28480 603 90599357
Somatic delusion 18.33 13.95 7 28480 607 90599353
Hyperhidrosis 18.22 13.95 88 28399 136217 90463743
Teeth brittle 18.05 13.95 7 28480 633 90599327
Logorrhoea 17.93 13.95 11 28476 2716 90597244
Infusion site abscess 17.70 13.95 6 28481 369 90599591
Living in residential institution 17.66 13.95 7 28480 671 90599289
Initial insomnia 17.63 13.95 18 28469 9292 90590668
Blood catecholamines increased 17.58 13.95 4 28483 54 90599906
Vision blurred 17.57 13.95 75 28412 110218 90489742
Thrombocytopenia 17.50 13.95 24 28463 208701 90391259
Crying 17.49 13.95 30 28457 25615 90574345
Pulmonary fibrosis 17.43 13.95 6 28481 107497 90492463
Obsessive-compulsive disorder 17.24 13.95 13 28474 4491 90595469
Poor quality sleep 16.99 13.95 29 28458 24664 90575296
Apathy 16.78 13.95 19 28468 11021 90588939
Dermatitis contact 16.71 13.95 21 28466 13574 90586386
Vitamin B6 deficiency 16.70 13.95 5 28482 205 90599755
Red blood cell sedimentation rate increased 16.50 13.95 3 28484 82592 90517368
Labelled drug-disease interaction issue 16.35 13.95 4 28483 75 90599885
Primary myelofibrosis 16.25 13.95 4 28483 77 90599883
Swelling 15.70 13.95 73 28414 418985 90180975
Cornea verticillata 15.69 13.95 5 28482 253 90599707
Wheezing 15.68 13.95 32 28455 238048 90361912
Illness 15.67 13.95 59 28428 81910 90518050
Nightmare 15.60 13.95 26 28461 21699 90578261
Unevaluable event 15.43 13.95 45 28442 54803 90545157
Camptocormia 15.06 13.95 5 28482 288 90599672
Product administration interrupted 14.89 13.95 19 28468 12473 90587487
Coma scale abnormal 14.70 13.95 13 28474 5613 90594347
Acquired haemophilia 14.59 13.95 7 28480 1062 90598898
Basophil percentage increased 14.47 13.95 4 28483 123 90599837
Clavicle fracture 14.32 13.95 11 28476 3905 90596055
Sleep attacks 14.32 13.95 4 28483 128 90599832
Energy increased 14.17 13.95 10 28477 3120 90596840
Dreamy state 14.01 13.95 3 28484 30 90599930

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 412.72 15.31 260 15586 57247 42548242
Hypersexuality 317.72 15.31 82 15764 1620 42603869
Impulse-control disorder 299.45 15.31 77 15769 1498 42603991
Dyskinesia 277.70 15.31 151 15695 25239 42580250
On and off phenomenon 243.50 15.31 78 15768 3389 42602100
Freezing phenomenon 221.11 15.31 63 15783 1826 42603663
Gambling disorder 211.34 15.31 60 15786 1716 42603773
Hallucination, visual 205.10 15.31 116 15730 20904 42584585
Dopamine dysregulation syndrome 180.20 15.31 42 15804 531 42604958
Muscle rigidity 132.52 15.31 72 15774 11987 42593502
Sudden onset of sleep 113.35 15.31 27 15819 377 42605112
Jealous delusion 112.76 15.31 27 15819 386 42605103
Stoma site discharge 106.88 15.31 34 15812 1442 42604047
Fall 98.20 15.31 247 15599 234273 42371216
Bradykinesia 93.62 15.31 44 15802 5392 42600097
Somnolence 89.98 15.31 176 15670 140929 42464560
Compulsive shopping 89.87 15.31 23 15823 438 42605051
Stoma site erythema 88.83 15.31 27 15819 983 42604506
Restless legs syndrome 70.08 15.31 44 15802 9570 42595919
Hyperkinesia 69.50 15.31 27 15819 2071 42603418
Device dislocation 65.15 15.31 39 15807 7792 42597697
Delusion 61.72 15.31 48 15798 14686 42590803
Aggression 61.65 15.31 79 15767 44084 42561405
Psychotic disorder 58.71 15.31 63 15783 29145 42576344
Confusional state 56.38 15.31 163 15683 167434 42438055
Serotonin syndrome 55.95 15.31 58 15788 25787 42579702
Abnormal dreams 55.68 15.31 36 15810 8235 42597254
Libido increased 52.61 15.31 18 15828 960 42604529
Stereotypy 51.23 15.31 17 15829 825 42604664
Balance disorder 51.05 15.31 75 15771 47570 42557919
Stoma site reaction 48.10 15.31 13 15833 308 42605181
Compulsions 46.62 15.31 12 15834 234 42605255
Dropped head syndrome 46.14 15.31 12 15834 244 42605245
Paraphilia 45.99 15.31 10 15836 90 42605399
Fibroma 44.80 15.31 13 15833 402 42605087
Orthostatic hypotension 44.74 15.31 56 15790 30514 42574975
Tremor 43.48 15.31 105 15741 96824 42508665
Gambling 43.41 15.31 11 15835 201 42605288
Mobility decreased 42.87 15.31 59 15787 35247 42570242
Febrile neutropenia 41.82 15.31 9 15837 185694 42419795
Memory impairment 41.26 15.31 70 15776 50152 42555337
Abnormal behaviour 41.19 15.31 50 15796 26401 42579088
Therapeutic product effect variable 41.06 15.31 21 15825 3088 42602401
Insomnia 40.67 15.31 116 15730 118137 42487352
Compulsive sexual behaviour 40.41 15.31 11 15835 268 42605221
Stoma site pain 40.18 15.31 14 15832 789 42604700
Gait disturbance 38.55 15.31 101 15745 97899 42507590
Tension 36.53 15.31 18 15828 2446 42603043
Behaviour disorder 36.28 15.31 26 15820 7028 42598461
Hypersomnia 35.65 15.31 35 15811 14583 42590906
Mania 34.99 15.31 30 15816 10517 42594972
Reduced facial expression 34.63 15.31 15 15831 1518 42603971
Alien limb syndrome 34.49 15.31 5 15841 0 42605489
Stoma site inflammation 33.36 15.31 11 15835 523 42604966
Disturbance in attention 31.96 15.31 47 15799 29819 42575670
Sleep attacks 31.84 15.31 8 15838 141 42605348
Speech disorder 31.41 15.31 46 15800 29075 42576414
Cognitive disorder 31.25 15.31 50 15796 34122 42571367
Irritability 31.17 15.31 45 15801 28083 42577406
Impulsive behaviour 30.93 15.31 16 15830 2409 42603080
Agitation 30.25 15.31 71 15775 64243 42541246
Middle insomnia 29.55 15.31 24 15822 7809 42597680
Parkinsonism hyperpyrexia syndrome 29.04 15.31 9 15837 350 42605139
Excessive sexual fantasies 28.37 15.31 5 15841 12 42605477
Anticholinergic syndrome 27.78 15.31 13 15833 1576 42603913
Nonspecific reaction 27.69 15.31 13 15833 1588 42603901
Drug withdrawal syndrome 27.65 15.31 37 15809 21512 42583977
Stoma site hypergranulation 27.46 15.31 8 15838 251 42605238
Embedded device 27.20 15.31 9 15837 433 42605056
Dystonia 26.42 15.31 28 15818 12762 42592727
Obsessive-compulsive disorder 26.15 15.31 21 15825 6722 42598767
Stress cardiomyopathy 26.14 15.31 15 15831 2770 42602719
Multiple organ dysfunction syndrome 25.65 15.31 3 15843 97032 42508457
Tic 25.53 15.31 14 15832 2369 42603120
Neutropenia 24.31 15.31 23 15823 199408 42406081
Urinary tract infection 23.73 15.31 86 15760 99198 42506291
Incorrect product dosage form administered 23.57 15.31 7 15839 235 42605254
Transvestism 23.20 15.31 4 15842 8 42605481
Paranoia 22.63 15.31 27 15819 13999 42591490
Progressive supranuclear palsy 22.52 15.31 5 15841 50 42605439
Diarrhoea 22.33 15.31 92 15754 460757 42144732
Gait inability 21.69 15.31 34 15812 22799 42582690
Medical device discomfort 21.69 15.31 5 15841 60 42605429
Thunderclap headache 21.67 15.31 6 15840 156 42605333
Exhibitionism 21.61 15.31 5 15841 61 42605428
Pyrexia 21.45 15.31 75 15771 393967 42211522
Parkinsonian rest tremor 21.41 15.31 7 15839 324 42605165
Generalised onset non-motor seizure 21.16 15.31 4 15842 16 42605473
Hypokinesia 21.08 15.31 22 15824 9849 42595640
Sexually inappropriate behaviour 20.57 15.31 8 15838 615 42604874
Torsade de pointes 19.89 15.31 20 15826 8574 42596915
Akinesia 19.76 15.31 12 15834 2460 42603029
Suspiciousness 19.63 15.31 7 15839 422 42605067
Hypomania 19.60 15.31 12 15834 2496 42602993
Theft 19.32 15.31 6 15840 235 42605254
Bipolar disorder 19.13 15.31 14 15832 3908 42601581
Stoma site haemorrhage 19.09 15.31 9 15837 1110 42604379
Nocturia 19.02 15.31 23 15823 12089 42593400
Rehabilitation therapy 19.00 15.31 9 15837 1121 42604368
Acute kidney injury 18.61 15.31 72 15774 367265 42238224
Salivary gland cancer stage IV 18.50 15.31 4 15842 35 42605454
Device kink 18.45 15.31 7 15839 503 42604986
Excessive masturbation 18.25 15.31 5 15841 125 42605364
Dysphagia 18.23 15.31 64 15782 72655 42532834
Oedema peripheral 18.13 15.31 99 15747 135977 42469512
Product dispensing error 18.09 15.31 18 15828 7621 42597868
Restlessness 17.99 15.31 36 15810 29213 42576276
Mydriasis 17.76 15.31 19 15827 8751 42596738
Psychomotor hyperactivity 17.52 15.31 21 15825 10937 42594552
Micturition disorder 17.20 15.31 11 15835 2469 42603020
Poor quality sleep 16.61 15.31 19 15827 9421 42596068
Toxicity to various agents 16.58 15.31 38 15808 229098 42376391
Neuroleptic malignant syndrome 16.41 15.31 29 15817 21443 42584046
Malignant neoplasm progression 16.39 15.31 10 15836 108390 42497099
Dementia 16.29 15.31 25 15821 16455 42589034
Suicidal ideation 16.29 15.31 47 15799 48114 42557375
Homosexuality 16.28 15.31 4 15842 64 42605425
Hallucinations, mixed 16.17 15.31 12 15834 3423 42602066
Logorrhoea 15.95 15.31 11 15835 2796 42602693
Hyperphagia 15.69 15.31 9 15837 1661 42603828
Dizziness 15.50 15.31 151 15695 249103 42356386

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 464.02 12.72 256 35095 51190 110502758
Hallucination 460.06 12.72 326 35025 101106 110452842
On and off phenomenon 405.66 12.72 118 35233 4306 110549642
Hallucination, visual 356.86 12.72 197 35154 39408 110514540
Impulse-control disorder 342.88 12.72 89 35262 2105 110551843
Dopamine dysregulation syndrome 340.18 12.72 70 35281 557 110553391
Freezing phenomenon 254.36 12.72 73 35278 2536 110551412
Hypersexuality 238.07 12.72 65 35286 1875 110552073
Gambling disorder 216.72 12.72 62 35289 2129 110551819
Compulsive shopping 215.22 12.72 51 35300 817 110553131
Fall 197.13 12.72 527 34824 602955 109950993
Jealous delusion 166.67 12.72 37 35314 436 110553512
Stoma site discharge 152.16 12.72 50 35301 2745 110551203
Restless legs syndrome 149.58 12.72 95 35256 24531 110529417
Bradykinesia 135.28 12.72 67 35284 10721 110543227
Hyperkinesia 130.35 12.72 46 35305 3138 110550810
Muscle rigidity 122.30 12.72 83 35268 23948 110530000
Stoma site erythema 115.76 12.72 38 35313 2079 110551869
Tremor 115.66 12.72 221 35130 202011 110351937
Delusion 104.42 12.72 75 35276 23680 110530268
Gait disturbance 104.00 12.72 256 35095 277952 110275996
Parkinsonism hyperpyrexia syndrome 96.22 12.72 25 35326 593 110553355
Full blood count abnormal 93.42 12.72 102 35249 55950 110497998
Somnolence 93.00 12.72 256 35095 297193 110256755
Gambling 92.97 12.72 22 35329 350 110553598
Behaviour disorder 81.42 12.72 46 35305 9601 110544347
Sudden onset of sleep 78.92 12.72 22 35329 686 110553262
Serotonin syndrome 75.73 12.72 94 35257 59059 110494889
Dystonia 71.35 12.72 62 35289 25743 110528205
Stereotypy 66.86 12.72 21 35330 996 110552952
Drug withdrawal syndrome 64.71 12.72 70 35281 37984 110515964
Aggression 63.17 12.72 86 35265 59124 110494824
Irritability 61.24 12.72 76 35275 47733 110506215
Balance disorder 60.07 12.72 122 35229 116438 110437510
Treatment failure 56.89 12.72 10 35341 277224 110276724
Psychotic disorder 55.89 12.72 75 35276 50862 110503086
Contraindicated product administered 55.44 12.72 7 35344 248260 110305688
Abnormal dreams 55.36 12.72 40 35311 12740 110541208
Hepatic enzyme increased 55.12 12.72 17 35334 320875 110233073
Impulsive behaviour 55.09 12.72 25 35326 3290 110550658
Systemic lupus erythematosus 54.83 12.72 8 35343 254330 110299618
Hand deformity 54.47 12.72 4 35347 218502 110335446
Withdrawal syndrome 53.84 12.72 58 35293 31322 110522626
Hyperglycaemia 53.60 12.72 97 35254 84993 110468955
Therapeutic product effect variable 53.23 12.72 23 35328 2695 110551253
Feeling abnormal 51.98 12.72 151 35200 180560 110373388
Dropped head syndrome 51.93 12.72 15 35336 533 110553415
Acute psychosis 51 12.72 27 35324 4960 110548988
Febrile neutropenia 48.91 12.72 20 35331 316747 110237201
Glossodynia 47.81 12.72 7 35344 221997 110331951
Helicobacter infection 46.29 12.72 3 35348 181874 110372074
Infusion related reaction 45.85 12.72 33 35318 381129 110172819
Product dose omission issue 45.08 12.72 213 35138 321569 110232379
Insomnia 44.35 12.72 230 35121 360360 110193588
Gastrooesophageal reflux disease 43.93 12.72 142 35209 179834 110374114
Lower respiratory tract infection 43.36 12.72 12 35339 243094 110310854
Abnormal behaviour 42.09 12.72 57 35294 38982 110514966
Compulsions 42.05 12.72 12 35339 408 110553540
Binge eating 41.38 12.72 13 35338 617 110553331
Speech disorder 41.10 12.72 72 35279 61497 110492451
Orthostatic hypotension 41.06 12.72 75 35276 66174 110487774
Pyrexia 40.66 12.72 149 35202 898116 109655832
Off label use 39.77 12.72 299 35052 1499886 109054062
Drug intolerance 39.50 12.72 43 35308 406469 110147479
Illusion 39.36 12.72 17 35334 1990 110551958
Sleep attacks 39.16 12.72 10 35341 221 110553727
Asthma 39.01 12.72 171 35180 250120 110303828
Joint swelling 38.61 12.72 51 35300 442794 110111154
Parkinsonian gait 38.29 12.72 14 35337 1058 110552890
Hypersomnia 38.19 12.72 46 35305 28015 110525933
Urinary tract infection 37.30 12.72 204 35147 326078 110227870
Tension 36.98 12.72 22 35329 5056 110548892
Exposure during pregnancy 36.70 12.72 5 35346 167419 110386529
Agitation 35.96 12.72 98 35253 112953 110440995
Stomatitis 35.75 12.72 21 35330 270221 110283727
Disturbance in attention 35.69 12.72 68 35283 61927 110492021
Libido increased 35.53 12.72 17 35334 2522 110551426
Obsessive-compulsive disorder 34.45 12.72 24 35327 7217 110546731
Tardive dyskinesia 34.30 12.72 31 35320 13548 110540400
Psychotic symptom 34.16 12.72 19 35332 3848 110550100
Irritable bowel syndrome 33.51 12.72 6 35345 164209 110389739
Stoma site pain 33.24 12.72 15 35336 1948 110552000
Product dispensing error 33.06 12.72 33 35318 16312 110537636
Reduced facial expression 32.42 12.72 18 35333 3633 110550315
Akinesia 32.34 12.72 18 35333 3649 110550299
Logorrhoea 32.30 12.72 20 35331 4937 110549011
Dementia 32.27 12.72 45 35306 31628 110522320
Stoma site reaction 32.26 12.72 10 35341 454 110553494
Posture abnormal 31.72 12.72 19 35332 4419 110549529
Mania 31.47 12.72 36 35315 20760 110533188
Muscle injury 31.35 12.72 4 35347 140803 110413145
Multiple sclerosis relapse 31.29 12.72 57 35294 50183 110503765
Parkinsonism 31.23 12.72 37 35314 22150 110531798
Inflammation 30.14 12.72 12 35339 193226 110360722
Completed suicide 30.04 12.72 155 35196 242226 110311722
Energy increased 29.61 12.72 17 35334 3657 110550291
Oromandibular dystonia 29.52 12.72 12 35339 1207 110552741
Impaired healing 29.43 12.72 13 35338 196704 110357244
Device dislocation 29.30 12.72 43 35308 31661 110522287
Rapid eye movement sleep behaviour disorder 29.12 12.72 10 35341 629 110553319
Wound 28.56 12.72 20 35331 234417 110319531
Muscle spasms 28.54 12.72 169 35182 277988 110275960
Periodic limb movement disorder 28.25 12.72 9 35342 447 110553501
Dizziness 28.22 12.72 344 35007 697849 109856099
Blood cholesterol increased 27.97 12.72 12 35339 184773 110369175
Rheumatoid arthritis 27.67 12.72 33 35318 299580 110254368
Polyp 27.63 12.72 24 35327 9956 110543992
Hyperphagia 27.56 12.72 16 35335 3515 110550433
Confusional state 26.95 12.72 248 35103 468432 110085516
Middle insomnia 26.91 12.72 33 35318 20469 110533479
Memory impairment 26.56 12.72 129 35222 196815 110357133
Depression 26.51 12.72 183 35168 317152 110236796
Death 26.39 12.72 340 35011 698529 109855419
Hallucinations, mixed 26.30 12.72 22 35329 8671 110545277
Movement disorder 26.17 12.72 44 35307 36360 110517588
Bursitis 25.96 12.72 5 35346 129913 110424035
Liver disorder 25.39 12.72 7 35344 142236 110411712
Parkinsonian rest tremor 25.22 12.72 8 35343 392 110553556
Alopecia 25.18 12.72 49 35302 364704 110189244
Progressive supranuclear palsy 25.15 12.72 7 35344 217 110553731
Catecholamines urine increased 25.11 12.72 5 35346 33 110553915
Stoma site infection 25.06 12.72 12 35339 1783 110552165
Cognitive disorder 25.02 12.72 73 35278 87438 110466510
Somatic delusion 24.22 12.72 9 35342 712 110553236
Pleurothotonus 24.07 12.72 13 35338 2485 110551463
Transvestism 23.80 12.72 4 35347 8 110553940
Surgery 23.41 12.72 45 35306 41238 110512710
Compulsive sexual behaviour 23.29 12.72 7 35344 286 110553662
Dependence 22.99 12.72 13 35338 2716 110551232
Apathy 22.72 12.72 27 35324 16212 110537736
Device occlusion 22.50 12.72 26 35325 15159 110538789
Resting tremor 22.49 12.72 11 35340 1712 110552236
Ill-defined disorder 22.48 12.72 11 35340 156842 110397106
Psychomotor hyperactivity 22.46 12.72 30 35321 20247 110533701
Medical device site dryness 22.44 12.72 5 35346 60 110553888
Device connection issue 22.42 12.72 10 35341 1264 110552684
Psoriatic arthropathy 22.41 12.72 18 35333 196743 110357205
Incorrect product dosage form administered 22.33 12.72 7 35344 330 110553618
Hypokinesia 22.22 12.72 31 35320 21795 110532153
Arthropathy 22.21 12.72 36 35315 287486 110266462
Excessive sexual fantasies 22.18 12.72 4 35347 14 110553934
Anxiety 22.10 12.72 187 35164 344891 110209057
Gastrointestinal disorder 21.96 12.72 27 35324 241925 110312023
Parkinsonian crisis 21.76 12.72 4 35347 16 110553932
Joint range of motion decreased 21.74 12.72 6 35345 121826 110432122
Neuroleptic malignant syndrome 21.66 12.72 39 35312 34020 110519928
Therapeutic response unexpected 21.54 12.72 32 35319 23811 110530137
Hypomania 21.36 12.72 21 35330 10189 110543759
Device issue 21.27 12.72 39 35312 34496 110519452
Infusion site abscess 21.27 12.72 7 35344 386 110553562
Restlessness 21.21 12.72 52 35299 56207 110497741
Sexually inappropriate behaviour 21.17 12.72 8 35343 663 110553285
Occipital neuralgia 20.79 12.72 8 35343 696 110553252
Eczema eyelids 20.70 12.72 7 35344 420 110553528
Blood catecholamines increased 20.60 12.72 5 35346 89 110553859
Neutropenia 20.49 12.72 57 35294 374563 110179385
Poor quality sleep 20.27 12.72 34 35317 28043 110525905
Nocturia 20.15 12.72 26 35325 16964 110536984
Extra dose administered 20.03 12.72 22 35329 12137 110541811
Hyperhidrosis 19.98 12.72 115 35236 187183 110366765
Malignant neoplasm progression 19.84 12.72 16 35335 174551 110379397
Camptocormia 19.78 12.72 7 35344 481 110553467
Limbic encephalitis 19.72 12.72 8 35343 800 110553148
Hypertension 19.65 12.72 90 35261 509994 110043954
Persecutory delusion 19.20 12.72 16 35335 6275 110547673
Rash 19.18 12.72 169 35182 820795 109733153
Obsessive thoughts 19.05 12.72 9 35342 1298 110552650
Excessive masturbation 19.03 12.72 5 35346 124 110553824
Nonspecific reaction 19.01 12.72 12 35339 3062 110550886
Hepatitis 19.01 12.72 3 35348 90051 110463897
Stoma site odour 18.99 12.72 5 35346 125 110553823
Quality of life decreased 18.91 12.72 23 35328 14146 110539802
Paranoia 18.76 12.72 29 35322 22345 110531603
Mucosal inflammation 18.59 12.72 4 35347 96137 110457811
Discomfort 18.41 12.72 25 35326 214682 110339266
Stoma site hypergranulation 18.33 12.72 7 35344 597 110553351
Interstitial lung disease 18.17 12.72 11 35340 139323 110414625
Patient elopement 17.97 12.72 6 35345 346 110553602
Device kink 17.91 12.72 10 35341 2039 110551909
Urticaria 17.82 12.72 48 35303 318809 110235139
Stoma site inflammation 17.82 12.72 8 35343 1027 110552921
Hallucination, auditory 17.78 12.72 31 35320 26366 110527582
Cerebral atrophy 17.74 12.72 18 35333 9067 110544881
Homosexuality 17.73 12.72 4 35347 51 110553897
Therapeutic response shortened 17.71 12.72 33 35318 29550 110524398
Thrombocytopenia 17.69 12.72 55 35296 348830 110205118
Anticholinergic syndrome 17.64 12.72 13 35338 4267 110549681
Suspected suicide 17.62 12.72 23 35328 15176 110538772
Stoma site irritation 17.60 12.72 6 35345 369 110553579
Dermatitis contact 17.57 12.72 22 35329 13931 110540017
Dysstasia 17.54 12.72 35 35316 32951 110520997
Stoma site extravasation 17.43 12.72 6 35345 380 110553568
Rehabilitation therapy 17.42 12.72 10 35341 2151 110551797
Pancytopenia 17.38 12.72 25 35326 209588 110344360
Hypertonia 17.05 12.72 17 35334 8389 110545559
Injury 16.92 12.72 19 35332 177246 110376702
Exhibitionism 16.88 12.72 4 35347 64 110553884
Dysphagia 16.83 12.72 95 35256 153505 110400443
Wound infection 16.75 12.72 5 35346 96460 110457488
Suspiciousness 16.71 12.72 7 35344 760 110553188
Salivary gland cancer stage IV 16.66 12.72 4 35347 68 110553880
Wrong product administered 16.63 12.72 19 35332 10941 110543007
Loss of consciousness 16.26 12.72 113 35238 196193 110357755
Grip strength decreased 16.20 12.72 3 35348 80171 110473777
Wheezing 16.16 12.72 36 35315 255194 110298754
Blister 16.16 12.72 30 35321 227346 110326602
Musculoskeletal pain 16.01 12.72 21 35330 183002 110370946
Paraphilia 15.95 12.72 4 35347 82 110553866
Multiple organ dysfunction syndrome 15.91 12.72 15 35336 151695 110402253
Crying 15.86 12.72 29 35322 25599 110528349
Labelled drug-disease interaction issue 15.68 12.72 4 35347 88 110553860
Infusion site induration 15.65 12.72 8 35343 1368 110552580
Generalised onset non-motor seizure 15.64 12.72 4 35347 89 110553859
Limb injury 15.50 12.72 36 35315 37600 110516348
Theft 15.37 12.72 5 35346 266 110553682
Tic 15.28 12.72 11 35340 3482 110550466
Suicidal ideation 15.24 12.72 65 35286 93872 110460076
Neutrophil count increased 15.22 12.72 34 35317 34618 110519330
Neutrophil count decreased 15.15 12.72 10 35341 120931 110433017
Hypersensitivity 15.12 12.72 72 35279 403926 110150022
Thunderclap headache 15.07 12.72 6 35345 572 110553376
Coma scale abnormal 14.99 12.72 17 35334 9709 110544239
Vitamin B6 deficiency 14.89 12.72 6 35345 590 110553358
Pulmonary fibrosis 14.86 12.72 7 35344 102035 110451913
Secondary hypertension 14.82 12.72 6 35345 597 110553351
Teeth brittle 14.64 12.72 6 35345 616 110553332
Haemorrhoids 14.56 12.72 34 35317 35638 110518310
Cornea verticillata 14.55 12.72 5 35346 315 110553633
Product administration interrupted 14.53 12.72 18 35333 11274 110542674
Mental impairment 14.49 12.72 26 35325 22613 110531335
Micturition disorder 14.44 12.72 12 35339 4686 110549262
Mood altered 14.27 12.72 25 35326 21350 110532598
Renal impairment 14.17 12.72 24 35327 188421 110365527
Obsessive-compulsive personality disorder 14.10 12.72 4 35347 133 110553815
Lactic acidosis 14.09 12.72 6 35345 92805 110461143
Initial insomnia 14.08 12.72 17 35334 10372 110543576
Postural reflex impairment 14.05 12.72 3 35348 29 110553919
Vomiting 13.97 12.72 206 35145 910469 109643479
Disorientation 13.96 12.72 52 35299 70619 110483329
Salivary hypersecretion 13.80 12.72 22 35329 17399 110536549
Female orgasmic disorder 13.79 12.72 3 35348 32 110553916
Unevaluable event 13.78 12.72 46 35305 59181 110494767
Nasal congestion 13.69 12.72 65 35286 98217 110455731
Nightmare 13.68 12.72 35 35316 38828 110515120
Syncope 13.61 12.72 111 35240 202425 110351523
Arthralgia 13.52 12.72 172 35179 779460 109774488
Toxicity to various agents 13.50 12.72 94 35257 480461 110073487
Lung disorder 13.48 12.72 23 35328 180024 110373924
Increased appetite 13.39 12.72 20 35331 14957 110538991
Obesity 13.37 12.72 10 35341 113341 110440607
Abdominal discomfort 13.15 12.72 73 35278 393785 110160163
Leukopenia 13.09 12.72 17 35334 148774 110405174
Drug reaction with eosinophilia and systemic symptoms 12.96 12.72 5 35346 82090 110471858
Therapeutic product effect delayed 12.86 12.72 11 35340 4468 110549480

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BC04 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA MoA N0000000117 Dopamine Agonists
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018726 Anti-Dyskinesia Agents
FDA EPC N0000175768 Nonergot Dopamine Agonist
CHEBI has role CHEBI:35470 central nervous system drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:51065 dopamine agonist
CHEBI has role CHEBI:66956 antidyskinesia agent

Related Drugs by ATC class:

N04BC Dopamine agonists 8 drugs
apomorphinebromocriptinecabergolinedihydroergocryptinepergolidepiribedilpramipexolerotigotine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Restless legs indication 32914008 DOID:0050425
Parkinson's disease indication 49049000 DOID:14330
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Orthostatic hypotension contraindication 28651003
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Psychotic disorder contraindication 69322001
Syncope contraindication 271594007
Drowsy contraindication 271782001
Central nervous system depression contraindication 418072004
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

ProductApplicantIngredients
CLEVOR Orion Corp. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.82 acidic
pKa2 9.18 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 8.14 IUPHAR IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 5.73 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 6.54 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR EC50 6.85 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 5.42 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 5.82 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.12 WOMBAT-PK
D(3) dopamine receptor GPCR AGONIST Ki 7.43 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 4.38 CHEMBL
5-hydroxytryptamine receptor 1D GPCR Ki 5.86 PDSP
Alpha-2C adrenergic receptor GPCR Ki 5.92 PDSP
D(4) dopamine receptor GPCR AGONIST Ki 6.07 WOMBAT-PK
D(1A) dopamine receptor GPCR Ki 4.49 CHEMBL
D(2) dopamine receptor GPCR Ki 5.57 CHEMBL
D(2) dopamine receptor GPCR IC50 5.17 CHEMBL
D(3) dopamine receptor GPCR Ki 7.53 CHEMBL

External reference:

IDSource
4024081 VUID
N0000022086 NUI
D00784 KEGG_DRUG
91374-20-8 SECONDARY_CAS_RN
4021058 VANDF
4024081 VANDF
C0244821 UMLSCUI
CHEBI:8888 CHEBI
CHEMBL589 ChEMBL_ID
CHEMBL1200411 ChEMBL_ID
DB00268 DRUGBANK_ID
C046649 MESH_SUPPLEMENTAL_RECORD_UI
5095 PUBCHEM_CID
7295 IUPHAR_LIGAND_ID
6436 INN_ID
030PYR8953 UNII
152951 RXNORM
11369 MMSL
136707 MMSL
25995 MMSL
5434 MMSL
d04215 MMSL
006273 NDDF
006274 NDDF
108473005 SNOMEDCT_US
108474004 SNOMEDCT_US
372499000 SNOMEDCT_US
030PYR8953 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 0228-3640 TABLET, FILM COATED, EXTENDED RELEASE 6 mg ORAL ANDA 18 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 0228-3658 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 18 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 0228-3659 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 18 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 0228-3660 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 18 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 0228-3661 TABLET, FILM COATED, EXTENDED RELEASE 12 mg ORAL ANDA 18 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8188 TABLET, FILM COATED 0.25 mg ORAL ANDA 27 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8189 TABLET, FILM COATED 0.50 mg ORAL ANDA 27 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8190 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8191 TABLET, FILM COATED 2 mg ORAL ANDA 27 sections
ROPINIROLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6373 TABLET, FILM COATED 0.25 mg ORAL ANDA 27 sections
ROPINIROLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6374 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-673 TABLET, FILM COATED 0.25 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-674 TABLET, FILM COATED 0.50 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-675 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-676 TABLET, FILM COATED 2 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-677 TABLET, FILM COATED 3 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-678 TABLET, FILM COATED 4 mg ORAL ANDA 28 sections
Ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 10135-679 TABLET, FILM COATED 5 mg ORAL ANDA 28 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-643 TABLET 1 mg ORAL ANDA 14 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-734 TABLET 2 mg ORAL ANDA 14 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-232 TABLET, FILM COATED 0.25 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-233 TABLET, FILM COATED 0.50 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-234 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-235 TABLET, FILM COATED 2 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-236 TABLET, FILM COATED 3 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-237 TABLET, FILM COATED 4 mg ORAL ANDA 27 sections
ropinirole HUMAN PRESCRIPTION DRUG LABEL 1 16729-238 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-792 TABLET, COATED 0.25 mg ORAL ANDA 22 sections
ropinirole hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-793 TABLET, FILM COATED 0.50 mg ORAL ANDA 12 sections
ROPINIROLE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-794 TABLET, COATED 1 mg ORAL ANDA 22 sections